CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues

What happened: Corcept Therapeutics reported third-quarter 2026 earnings of $1.01 per share, beating the Zacks Consensus Estimate of 68 cents, on revenues of $340.5 million. Growth came from higher Korlym sales and uptake of newly launched Lifyorli. Key numbers: EPS $1.01 vs. 68 cents estimate, up 531.3% year over year from 16 cents. Why it matters: Lifyorli, approved in March 2026, has drawn more than 2,300 patients and more than 1,700 prescribing physicians since its April 1 launch. Corcept reiterated its 2026 revenue outlook and carries a Zacks Rank #3 (Hold). Market: -7.7% today ($75.60), +97.9% YTD, 0.9x vol — as of 16:18 UTC Verified: Q3_2026 (Nov 3) EPS $1.01 vs $0.84 est, +20.2% beat; next print ~Feb 2

Corcept Therapeutics reported third-quarter 2026 earnings of $1.01 per share, beating the Zacks Consensus Estimate of 68 cents, on revenues of $340.5 million. Growth came from higher Korlym sales and uptake of newly launched Lifyorli.

Lifyorli, approved in March 2026, has drawn more than 2,300 patients and more than 1,700 prescribing physicians since its April 1 launch. Corcept reiterated its 2026 revenue outlook and carries a Zacks Rank #3 (Hold). Market: -7.7% today ($75.60), +97.9% YTD, 0.9x vol — as of 16:18 UTC Verified: Q3_2026 (Nov 3) EPS $1.01 vs $0.84 est, +20.2% beat; next print ~Feb 2